Authors
Jing Liu, Haoyang Wang, Xiqiang Wang, Wei Wu, Yong Zhang, Shuo Pan, Yujie Xing, Sen Ma, Zhongwei Liu
Published in
Aging cell. Volume 25. Issue 11.
Abstract
Macrophage inflammation and vascular smooth muscle cell (VSMC) senescence contribute to atherosclerotic plaque vulnerability. We investigated whether matrine-loaded macrophage membrane-functionalized liposomes (M-DTLPs) suppress macrophage Dll4-dependent signaling, reduce VSMC senescence, and improve plaque stability-associated features in experimental atherosclerosis. Non-targeted liposomes (NTLPs), macrophage membrane-functionalized liposomes (DTLPs), matrine-loaded non-targeted liposomes (M-NTLPs), and M-DTLPs were evaluated. Formulation properties, matrine loading, long-term stability, release, macrophage uptake, Dll4 loss-of-function and overexpression rescue, VSMC senescence, plaque burden and composition, plaque-macrophage localization, pharmacokinetics, and systemic safety were assessed in vitro and in atherosclerosis-prone mice. DTLPs and M-DTLPs retained nanoscale size, low polydispersity, spherical morphology, macrophage membrane-associated F4/80 and CD68 signals, and sustained matrine release. Membrane-functionalized formulations showed enhanced uptake by M1 macrophages. M-DTLPs reduced macrophage Dll4 and VSMC HES1, p21, and p16; Dll4 knockdown reproduced these effects, whereas Dll4 overexpression partially reversed the M-DTLP response. M-DTLPs also reduced SA-β-galactosidase positivity and SASP-related IL-6 and IL-1β while increasing EdU incorporation. In vivo, M-DTLPs reduced lesion and lipid burden, increased collagen and ACTA2-positive plaque area, increased fibrous-cap thickness, reduced necrotic-core area, and decreased ACTA2/p21 double-positive VSMCs. M-DTLPs showed greater plaque-associated and CD68-associated localization than M-NTLPs, while major pharmacokinetic parameters remained comparable between the two liposomal matrine formulations. No overt biochemical, histological, body-weight, or serum-lipid safety signal was observed. M-DTLPs combine macrophage membrane-functionalized delivery with matrine pharmacology to suppress a Dll4-dependent macrophage-to-VSMC senescence program and promote a plaque phenotype associated with greater structural stability in preclinical atherosclerosis.
PMID:
43046695
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0